newsfilter
← Latest News
Business Wire·

Sierra Oncology Provides Update to Momelotinib Development Timeline and Closes on $34 Million in Additional Funding

Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today updated guidance on the development timeline for its lead product candidate, momelotinib. The c